Allergy/Imm Medical News about omalizumab

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update
Respiratory Medicine, 06/30/09

Holgate S et al. - Based on clinical trial data analysis, it is recommended that treatment response is evaluated by the physician after 16 weeks of therapy. Treatment should only be continued in responders, i.e. those judged by the physician to have achieved a marked improvement or complete asthma control. Omalizumab is generally well tolerated. Anaphylactic-like reactions are rare and less common than encountered with other biologics.

<< Previous
High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune...

Next >>
Clinicoepidemiological Scoring System for Early Diagnosis of...

Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy
International Archives of Allergy and Immunology, 10/21/09 Relevance Score: 87%

Relationship between pretreatment specific IgE and the response to omalizumab therapy
Allergy, 11/12/09 Relevance Score: 85%

Effects of omalizumab on markers of inflammation in patients with allergic asthma
Allergy, 11/16/09 Relevance Score: 84%

“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
Respiratory Medicine, 10/13/09 Relevance Score: 84%

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Allergy and Asthma Proceedings, 10/12/09 Relevance Score: 83%